These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37835003)

  • 21. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
    Walkey AJ; Fein D; Horbowicz KJ; Farber HW
    Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review.
    Feenstra J; Hopkins P; Trotter M; O'Brien K
    Intern Med J; 2020 Nov; 50(11):1377-1384. PubMed ID: 31661174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epoprostenol treatment in children with severe pulmonary hypertension.
    Lammers AE; Hislop AA; Flynn Y; Haworth SG
    Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
    Sarangarm P; Elwood K
    Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of pulmonary hypertension].
    Damps-Konstańska I; Konstański Z; Jassem E
    Wiad Lek; 2007; 60(11-12):545-9. PubMed ID: 18540180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.
    Ussavarungsi K; Burger CD
    Pulm Circ; 2014 Sep; 4(3):520-6. PubMed ID: 25621166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.
    Rich S; Pogoriler J; Husain AN; Toth PT; Gomberg-Maitland M; Archer SL
    Chest; 2010 Nov; 138(5):1234-9. PubMed ID: 21051399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension.
    Satoh M; Aso K; Nakayama T; Saji T
    Endocr J; 2017 Dec; 64(12):1173-1180. PubMed ID: 28890480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report.
    Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D
    J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost-A Multicentre, Retrospective Study.
    Camara RP; Coelho FDN; Cruz-Martins N; Marques-Alves P; Castro G; Baptista R; Ferreira F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension.
    Akagi S; Ogawa A; Miyaji K; Kusano K; Ito H; Matsubara H
    Ann Am Thorac Soc; 2014 Jun; 11(5):719-27. PubMed ID: 24716663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe thrombocytopenia in patients with idiopathic pulmonary arterial hypertension provided several strategies for lung transplantation.
    Kobayashi T; Shigeta A; Terada J; Tanabe N; Sugiura T; Sakao S; Taniguchi K; Oto T; Tatsumi K
    Pulm Circ; 2020; 10(4):2045894020969103. PubMed ID: 33282197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol.
    Rossi R; Coppi F; Sgura F; Monopoli D; Boriani G
    Pulm Pharmacol Ther; 2018 Apr; 49():147-151. PubMed ID: 28642014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.